Skip to content
Open access

Clinical Trial: Phase 3 Trial of Resmetirom Versus Placebo in Metabolic Dysfunction‐Associated Steatohepatitis—Reanalysis of Fibrosis Stage 2–3 Subset

Jul 2026 · Alimentary Pharmacology and Therapeutics · Vol 64, pp. 919 - 929 · 2 citations · 24 references
Medicine

Abstract

Resmetirom is an oral thyroid hormone receptor beta agonist clinically used to treat metabolic dysfunction‐associated steatohepatitis (MASH) among adults with stage F2 or F3 fibrosis.

Read PDF

Similar papers

Open access Oct 2026

Study design of the phase III ADELA trial of elacestrant with or without everolimus in ESR1-mutated ER+/HER2- advanced breast cancer after progression on endocrine therapy plus a CDK4/6 inhibitor.

CLINICAL TRIAL REGISTRATION www.clinicaltrials.gov identifier is NCT06382948; EU Clinical Trials identifier is EUCT 2024-512926-27-00.

J. Pérez-García, A. Llombart-Cussac, E. López-Miranda et al. · 0 citations
Open access Oct 2026

Open-label extension study of leniolisib in activated PI3Kδ syndrome: Long-term efficacy and safety

Leniolisib, a PI3Kδ inhibitor, improves the pathophysiology of APDS. This publication demonstrates the safety and efficacy of leniolisib in patients with APDS ≥12 years of age receiving up to 7 years of treatment, illustrating a positive tolerability profile and sustained disease burden reduction.

V. K. Rao, A. Šedivá, V. Dalm et al. · 0 citations
Open access Oct 2026

Early Time Course of Symptom Improvement With Remibrutinib in Chronic Spontaneous Urticaria: Pooled Post Hoc Analyses of the REMIX-1/2 Phase 3 Studies.

We undertook a post hoc, sponsor‐funded analysis of data from two recent clinical trials in CSU. Remibrutinib numerically improved CSU symptoms at 12 h; meaningful effects persisted from Day‐2 through Week‐52.

Gordon Sussman, N. Chapman-Rothe, Tao Ding et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.